MYO1G and melanoma: Robust correlations of MYO1G gene expression and promoter hypomethylation with clinicopathological features and anti-tumor immune response firstly demonstrate that MYO1G gene expression and promoter hypomethylation are potential predictive biomarkers for immune cell infiltration, prognosis and immunotherapy response in melanoma.